de Lloyd Lucy, Jenkins Peter V, Bell Sarah F, Mutch Nicola J, Martins Pereira Julia Freyer, Badenes Pilar M, James Donna, Ridgeway Anouk, Cohen Leon, Roberts Thomas, Field Victoria, Collis Rachel E, Collins Peter W
Department of Anaesthetics and Pain Control, Cardiff and Vale University Health Board, Heath Park, Cardiff, UK.
Department of Haematology, Cardiff and Vale University Health Board, Heath Park, Cardiff, UK; Institute of Infection and Immunity, School of Medicine, Cardiff University, UK.
J Thromb Haemost. 2023 Apr;21(4):862-879. doi: 10.1016/j.jtha.2022.11.036. Epub 2022 Dec 22.
Postpartum hemorrhage (PPH) may be exacerbated by hemostatic impairment. Information about PPH-associated coagulopathy is limited, often resulting in treatment strategies based on data derived from trauma studies.
To investigate hemostatic changes associated with PPH.
PATIENTS/METHODS: From a population of 11 279 maternities, 518 (4.6%) women were recruited with PPH ≥ 1000 mL or placental abruption, amniotic fluid embolism, or concealed bleeding. Routine coagulation and viscoelastometric results were collated. Stored plasma samples were used to investigate women with bleeds > 2000 mL or those at increased risk of coagulopathy defined as placenta abruption, amniotic fluid embolism, or need for blood components. Procoagulant factors were assayed and global hemostasis was assessed using thrombin generation. Fibrinolysis was investigated with D-dimer and plasmin/antiplasmin complexes. Dysfibrinogenemia was assessed using the Clauss/antigen ratio.
At 1000 mL blood loss, Clauss fibrinogen was ≤2 g/L in 2.4% of women and 6/27 (22.2%) cases of abruption. Women with very large bleeds (>3000 mL) had evidence of a dilutional coagulopathy, although hemostatic impairment was uncommon. A subgroup of 12 women (1.06/1000 maternities) had a distinct coagulopathy characterized by massive fibrinolysis (plasmin/antiplasmin > 40 000 ng/mL), increased D-dimer, hypofibrinogenemia, dysfibrinogenemia, reduced factor V and factor VIII, and increased activated protein C, termed acute obstetric coagulopathy. It was associated with fetal or neonatal death in 50% of cases and increased maternal morbidity.
Clinically significant hemostatic impairment is uncommon during PPH, but a subgroup of women have a distinct and severe coagulopathy characterized by hyperfibrinolysis, low fibrinogen, and dysfibrinogenemia associated with poor fetal outcomes.
止血功能障碍可能会加剧产后出血(PPH)。关于PPH相关凝血病的信息有限,这常常导致基于创伤研究数据的治疗策略。
研究与PPH相关的止血变化。
患者/方法:在11279例产妇中,招募了518例(4.6%)PPH≥1000 mL或有胎盘早剥、羊水栓塞或隐性出血的妇女。整理常规凝血和粘弹性测定结果。储存的血浆样本用于研究出血量>2000 mL的妇女或凝血病风险增加的妇女,凝血病风险增加定义为胎盘早剥、羊水栓塞或需要血液成分。检测促凝血因子,并使用凝血酶生成评估整体止血情况。用D-二聚体和纤溶酶/抗纤溶酶复合物研究纤维蛋白溶解。使用Clauss/抗原比值评估异常纤维蛋白原血症。
失血1000 mL时,2.4%的妇女和6/27例(22.2%)胎盘早剥病例的Clauss纤维蛋白原≤2 g/L。出血量非常大(>3000 mL)的妇女有稀释性凝血病的证据,尽管止血功能障碍并不常见。12名妇女(1.06/1000例产妇)组成的亚组有一种独特的凝血病,其特征为大量纤维蛋白溶解(纤溶酶/抗纤溶酶>40000 ng/mL)、D-二聚体增加、低纤维蛋白原血症、异常纤维蛋白原血症、因子V和因子VIII降低以及活化蛋白C增加,称为急性产科凝血病。50%的病例与胎儿或新生儿死亡以及孕产妇发病率增加有关。
临床上显著的止血功能障碍在PPH期间并不常见,但有一小部分妇女有一种独特且严重的凝血病,其特征为纤维蛋白溶解亢进、纤维蛋白原水平低和异常纤维蛋白原血症,与不良胎儿结局相关。